/L, and a clinically relevant response as increase to [ 30 9 10 9 /L with twofold increase from baseline and absence of bleeding [4] . Physician-determined reduction in severity and frequency of bleeds, parental perception on improvement in quality of life, breakthrough bleeding warranting additional therapy, and significant adverse events were recorded. Repeated measure ANOVA was used to analyze change in the platelet counts with time (SPSSv20).
Eight children were enrolled (Table 1) . Median duration of thrombocytopenia prior to initiating 6MP was 3.2-years. Median platelet count was 4 9 10 9 /L (IQR: 2;6). Serial counts demonstrated that no patient achieved complete response (Table 1) . Clinically relevant response was seen in 2/8 (25%) patients at 1 and 2-months with increase in platelet count to 92 9 10 9 /L and 53 9 10 9 /L, respectively. However, counts for both decreased within a month while on treatment. Overall, there was no significant increase in platelet counts at 1, 2, 3, 4 or 6-months (p = 0.42). There was a transient reduction in the clinical severity of bleeds and improvement in quality of life in 3/8 (37.5%) children, 1-month following initiation of 6-MP, only one of whom had an increase in counts to 92 9 10 9 /L. Significant bleeding (grade 4) while on 6MP was documented in 3/8 (37.5%) children, warranting additional treatment. No significant adverse event was reported other than reversible, asymptomatic leucopenia in 1/8 (12.5%).
The purine metabolites 6MP and azathioprine have immunosuppressive effects on B and T-lymphocytes. Given the rarity of serious bleeds in chronic ITP, the latter itself being uncommon in children, prospective studies on the use of 6MP have been performed in small cohorts and are infrequently reported. Sobota et al. [3] had reported response in 85% children with chronic ITP with a mean increase of 162 9 10 9 /L, time to response of 2.7 ± 1.5-months, duration of response of 16-months, and continued disease remission after stopping therapy in 12.5%. Azathioprine is a related agent which is slowly but completely metabolized to 6MP and is supposed to have a better safety profile. It has been documented to produce response-rates between 51 and 87% in adults, and 80% in a small series of 5 children [5] . The lack of response to purine metabolite in our study can be explained by two possible reasons. Firstly, the duration of thrombocytopenia prior to initiation of 6MP was prolonged in the index study (3.2-years, vs 18.7-months in the study by Sobota et al. [3] ). Early suppression of the underlying autoimmune mechanism could have provided a benefit in the previous study. However spontaneous remissions, and a waxing and waning course are well known in chronic ITP, and previous reports of response could have been merely fortuitous.
In conclusion, despite small numbers, the total lack of response to 6MP in children with chronic ITP in the current study was disheartening. Larger prospective studies would need multi-center collaboration and are indicated to confirm or refute the efficacy of 6MP in chronic ITP.
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